NSE/ALKEM

ALKEMAlkem Laboratories Ltd

Healthcare · NSE

₹5,582+0.22%

52-wk low52-WEEK RANGE52-wk high

₹4,732.8+17.9% from low ·-5.2% from high₹5,890

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

ALKEM+15.36% · 1Y

Range high ₹5,933.5Range low ₹4,716.2Latest ₹5,582252 bars · daily-close · NSE bhavcopy + 10Y history

HealthcareDrug Manufacturers - Specialty & GenericLargecapLow Risk

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite75/100

Performance

Medium

Middle-of-the-pack performance.

· 52w return +11.6%
· Just above 200-DMA (+3.6%)

Valuation

Low

Appears to be fairly valued to cheap vs peers.

· P/E 28.5 vs sector median 37.8 — 25% cheaper
· P/B 5.06 below sector median 5.81

Growth

Medium

Steady but not standout growth.

· Revenue YoY +2.3% — slow
· Profit YoY +20.6%

Profitability

High

Showing good signs of profitability & efficiency.

· ROE 17.8%
· Net margin 16.7% — strong pricing power

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeB(73/100)

Durability

84/100

Financially resilient — strong quality + solvency profile.

Show 4 drivers

Piotroski F-score6/9 (67pt)
Altman Z" score5.71 (100pt)
Debt/Equity0.17 (100pt)
ROE17.8% (71pt)

Valuation

67/100

Fairly priced — not a bargain, not stretched.

Show 4 drivers

P/E vs sector (28.5 / 37.8)75% (93pt)
P/B5.06 (70pt)
Dividend yield0.91% (23pt)
EV/EBITDA22.7 (35pt)

Momentum

68/100

Constructive setup — momentum building, not extended.

Show 5 drivers

52w change+11.6% (60pt)
DMA-trend alignmentup (75pt)
RSI (14)59.6 (95pt)
Price vs 200-DMA+2.7% (50pt)
MACD regimebullish (75pt)

Valuation positioning

Current ratio vs sector peer distribution

P/E (TTM)28.52

FAIR

CheapestP/E 28.5 near sector median.Most expensive

P/B5.06

FAIR

CheapestP/B 5.06 at 42th %ile of sector.Most expensive

EV/EBITDA22.72

OVERVALUED

Monthly seasonality

Avg monthly return over 10 years · historical — not a forecast

Best: Jul +7.77% · Worst: Oct -2.03%

Jan

+0.8%

50% win

Feb

+1.4%

50% win

Mar

-0.5%

50% win

Apr

-0.0%

40% win

May

-0.7%

30% win

Jun

+0.9%

Monthly return distribution

Distribution of 120 monthly returns

Mean

+1.54%

Median

+1.38%

Std dev

7.08%

Best

+28.4%

Worst

-12.9%

% positive

53%

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 4

Lean balance sheet (D/E 0.17)
Low leverage means earnings are less sensitive to rate cycles
Strong net margin (16.7%)
High margin indicates pricing power + operating efficiency
Bankruptcy risk low (Altman Z″ 5.71)
Z″ above 2.60 sits squarely in the 'safe' zone
Top quartile ROE in Healthcare
Rank 5 of 24 peers

WEAKNESSES · 0

No material weaknesses flag from the numbers

OPPORTUNITIES · 0

No strong near-term catalysts visible

THREATS · 0

No immediate threats from the data

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

+0.2%

+2.6%

+4.2%

-3.6%

+2.2%

+15.4%

+20.9%

+14.7%

10Y

+15.3%

Fundamentals

VALUATION

Market cap

₹67,578 Cr

P/E (TTM)

28.5

P/E (fwd)

29.7

next 12m

P/B

5.06

EV/EBITDA

22.7

Book value

₹1116.26

per share

PROFITABILITY · QUALITY

ROE

17.8%

ROCE

—

Net margin

16.7%

Op margin

19.6%

Gross margin

62.9%

D/E

0.17

GROWTH · MARKET

Rev YoY

+2.3%

Profit YoY

+20.6%

Div yield

0.91%

Payout

22.7%

52w change

+11.6%

Beta

0.32

defensive

Pros and cons

Auto-derived from ratios · not a buy/sell recommendation

PROS · 2

+Trading at -24.6% vs sector median P/EP/E 28.5 vs Healthcare median 37.8 — relative value on earnings
+Nearly debt-free (D/E 0.17)Low financial risk — funds growth from internal accruals, resilient in downturns

CONS · 0

No material concerns surface from the ratios alone — still layer qualitative research.

Sector-relative context

Healthcare · 24 peers

P/E (TTM)

This stock

28.52

Sector median

37.85

Rank 9/24 (67th %ile)

ROE

This stock

17.8%

Sector median

13.8%

Rank 20/24 (21th %ile)

P/B

This stock

5.06

Sector median

5.81

Rank 10/24 (63th %ile)

Quality score · Piotroski F-score

6 / 9

Decent quality — clears Piotroski bar

✓Profitable (positive net income)· Most basic check — company makes money
✓Positive return on assets· Assets generate returns
✓Positive operating cash flow· Profits are backed by real cash, not accruals
✗Operating CF exceeds net profit· Healthy cash conversion — no aggressive revenue recognition
✗Long-term debt decreased YoY· Deleveraging — lower refinancing risk
✓ROA improved YoY· Getting more productive with the asset base
✓Operating margin expanded YoY· Pricing power or cost discipline
✗

Forensic score · Altman Z″ (emerging markets)

Bankruptcy-risk predictor · 1995 Altman emerging-market revision

SAFE5.71

Z″ = 5.71 — well inside the SAFE zone. Low bankruptcy risk signal across liquidity, profitability and solvency inputs.

Component	Ratio	Weight	Contribution
Working Capital / Total Assets (A)	0.366	×6.56	2.402
Retained Earnings / Total Assets (B)	0.469	×3.26	1.528
EBIT / Total Assets (C)	0.126	×6.72	0.845
Book Equity / Total Liabilities (D)	0.888	×1.05	0.933

Zones: Z″ ≥ 2.60 safe · 1.10–2.60 grey · < 1.10 distress. All four inputs derived from latest annual filing.

Analyst consensus

21 analysts · HOLD

Target mean

₹5930.33

Target high

₹6913.00

Target low

₹4360.00

Upside vs today

+4.9%

Street consensus target is +4.9% vs current price. Consensus is a lagging sentiment read, not a forecast.

Company + balance sheet snapshot

Industry

Drug Manufacturers - Specialty & Generic

Employees

18,785

Shares out

Revenue (TTM)

₹14,253 Cr

EBITDA

₹2,835 Cr

Total debt

₹2,356 Cr

Cash

₹5,152 Cr

Net debt

₹-2,796 Cr

Quarterly results

Last 6 quarters · ₹ Cr (Screener.in-grade depth)

Metric	2024-Q3	2024-Q4	2025-Q1	2025-Q2	2025-Q3	2025-Q4
Revenue	—	3,374	2,984	3,371	4,001	3,737
Operating profit	—	674	308	651	827	733
OPM %	—	20.0%	10.3%	19.3%	20.7%	19.6%

Annual P&L

Last 4 years · ₹ Cr · all line items

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Revenue	10,512	11,440	12,439	12,805
Operating profit	1,769	1,334	1,985	2,184
OPM %	16.8%	11.7%	16.0%	17.1%
Interest	41	94	96	87

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
ALKEMTHIS Alkem Laboratories Limited	₹5,582	+11.6%	67,578	28.5	5.06	17.8%	0.17	+2.3%
DIVISLAB Divi's Laboratories Limited	₹6,229	+5.7%	1,66,714	67.2	10.81	16.1%	0.01	+12.3%
APOLLOHOSP Apollo Hospitals Enterprise Limited	₹7,699	+7.8%	1,10,096	61.0	12.11	19.8%	0.84	+17.2%
LUPIN Lupin Limited	₹2,326.1	+15.8%	1,06,756	23.0	5.43	—	0.32	+13.5%
DRREDDY Dr. Reddy's Laboratories Limited	₹1,235.7	+5.0%	1,02,626	18.2	2.76	16.1%	0.18	+4.4%
CIPLA Cipla Limited	₹1,240.8	-17.9%	99,317	21.9	3.02	13.8%	0.01	0.0%
MAXHEALTH Max Healthcare Institute Limited	₹1,007.65	-6.1%	98,448	69.7	9.85	—	0.33	+30.0%
MANKIND Mankind Pharma Limited	₹2,125	-17.9%	87,619	49.2	5.73	—	0.54	+18.1%
AUROPHARMA Aurobindo Pharma Limited	₹1,386	+15.4%	80,209	23.0	2.29	9.9%	0.22	+9.4%

ASK AXEL

Dig deeper into ALKEM

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for ALKEM — all in one sourced reply.

Ask free in chat

Run these tools on ALKEM

Historical return →

"If I had bought ALKEM in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on ALKEM

Brokerage + charges →

All-in cost for trading ALKEM

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Quarter	EPS estimate	EPS actual	Surprise %
-1q	57.97	56.88	-1.9%
-2q	60.55	63.99	+5.7%
-3q	45.80	54.62	+19.3%
-4q	29.48	25.57	-13.3%

Date	Amount
2026-02-20	₹43.00
2025-08-08	₹8.00
2025-02-14	₹37.00
2024-08-09	₹5.00
2024-02-16	₹35.00
2023-08-10	₹10.00
2023-02-17	₹40.00
2022-08-08	₹4.00
2022-02-10	₹30.00
2021-08-09	₹5.00
2021-02-11	₹25.00
2020-08-10	₹3.00
2020-02-13	₹22.00
2019-08-19	₹8.00
2019-02-15	₹8.00
2018-08-23	₹7.00
2018-02-16	₹6.00
2017-08-31	₹9.00
2016-11-23	₹6.00

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Equity capital	24	24	24	24
Reserves	6,594	7,052	8,310	9,973
Borrowings	2,668	1,397	1,418	1,381
Other liabilities	8	-0	26	22
Total liabilities	14,069	13,757	15,575	17,691
Fixed assets	2,766	2,514	2,596	2,932
CWIP	339	310	187	546
Investments	911	565	405	1,036
Other assets	0	-0	-0	-0
Total assets	14,069	13,757	15,575	17,691

Metric	2022-FY	2023-FY	2024-FY	2025-FY
CF Operating	1,111	1,683	1,948	1,913
CF Investing	-1,435	113	-1,009	-1,299
CF Financing	380	-1,761	-1,145	-811
Net cash flow	58	42	-207	-186
Free cash flow	772	1,450	1,689	1,237

Metric	2025-FY	2024-FY	2023-FY	2022-FY
OPM %	17.1%	16.0%	11.7%	16.8%
Net margin %	16.9%	14.4%	8.6%	15.7%
ROE %	23.6%	23.3%	14.4%	24.9%
ROCE %	24.7%	23.3%	15.8%	20.3%
Debt / Equity	0.14	0.17	0.20	0.40
Interest coverage	30.0×	22.1×	14.9×	46.2×
Revenue growth YoY	+2.9%	+8.7%	+8.8%	—
Profit growth YoY	+20.6%	+82.5%	-40.2%	—

ALKEMAlkem Laboratories Ltd

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Analyst consensus

Company + balance sheet snapshot

Quarterly results

Annual P&L

Peer comparison · Healthcare

Ask Axel about ALKEM

Recent news

Dig deeper into ALKEM

Run these tools on ALKEM

Technical snapshot

Earnings history + surprises

Dividends + splits history

Stock scorecard

Recent news

SWOT analysis

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Analyst consensus

Company + balance sheet snapshot

Quarterly results

Annual P&L

Balance sheet

Cash flow statement

Ratios

Peer comparison · Healthcare